Zoledronic Acid And Ibandronate In Treatment Of Bone Metastasis Of Breast Cancer Retrospective Study

Objective:Evaluation of bone metastasis of breast cancer patients receiving zoledronic acidand ibandronate efficacy and safety after the treatment.Methods:A retrospective analysis of the First Affiliated Hospital of Dalian MedicalUniversity from2005January in Department of oncology-2010year in January201cases of bone metastasis in breast cancer patients, all patients received bisphosphonatetherapy, divided into zoledronic acid group103cases, ibandronate group98cases,using SPSS17.0statistical analysis, two groups of clinical the collected data wereanalyzed, compared with two groups of analgesic efficacy (remission rate), lesioncontrol and repair of bone metastasis (efficiency) and the incidence of adverse reactionsof two drugs to evaluate the effectiveness, safety.Results:1, analgesic efficacy: zoledronic acid group was (CR+PR)70.8%, ibandronategroup efficiency (CR+PR) of67.3%, the value of=0.293P=0.588chi-square (P>0.05);zoledronic acid clinical benefit rate (89.3%CR+PR+SD), clinical benefit rate ofibandronic acid group (CR+PR+SD)84.7%, value=0.491P=0.484chi-square (P>0.05).No statistical significance between the two groups in the rate, clinical benefit ratedifference.。2, bone lesion control and repair situation: divided into bisphosphonates combinedwith chemotherapy, endocrine therapy group, chemotherapy group of zoledronic acidefficiency (CR+PR)37.5%, ibandronate efficiency (CR+PR) is31.2%, the value of=1.058P=0.304chi-square (P>0.05), no significant difference between two groups.Combined with endocrine therapy group of zoledronic acid efficiency (CR+PR)33.4%, ibandronate efficiency (CR+PR) is40.1%, the value of=0.440P=0.507chi-square(P>0.05). No statistically significant difference between two groups。3, The incidence of adverse reactions, the adverse reaction of zoledronic acidgroup the rate is16.5%, the adverse reaction of ibandronic acid was10.2%, the mainmanifestations were fever, fatigue, muscle and joint pain, nausea, rash, asymptomatichypocalcemia, hypophosphatemia,4cases above40degree heat which zoledronic acidgroup and8cases of fever patients, high occurrence rate is3.9%, ibandronate groupfound no obvious fever, liver and kidney function before and after the two groups hadno obvious changes in contrast, X2=1.714, P=0.190(P>0.05), the incidence of adversereactions of the two groups were not statistically significant.Conclusions:1For zoledronic acid and ibandronic acid as adjuvant therapy of breast cancer withbone metastasis good analgesia.2The two drugs have synergistic effect with chemotherapy, endocrine therapy.3Two medicine there is no statistical significant difference in security, patients cantolerate, zoledronic acid group slightly high than that of ibandronate group, high feverwere improved by symptomatic treatment, the other adverse reaction without specialtreatment.4Zoledronic acid intravenous drip in short time (more than15min), is moreconvenient to use the two can be used as first choice for the treatment of bonemetastasis of breast cancer.